Comment on the article of A.Yu. Yakovlev et al. “Clinical efficacy of metabolically active fluid therapy in patients with fat embolism syndrome”

Yu.P. Orlov


Received: 14.03.2018


References

  1. Bulger E.M., Smith D.G., Maier R.V., Jurkovich G.J. Fat embolism. A 10 year review. Arch. Surg. 1997; 132: 435–439.
  2. Kwiatt M.E., Seamon M.J. Fat embolism syndrome. Int. J. Crit. Illn. Inj. Sci. 2013; 3: 64–68.
  3. Liu X.M, Huang J.C., Wang G.D.,et al. Clinical effectiveness analysis of dextran 40 plus dexamethasone on the prevention of fat embolism syndrome. Int. J. Clin. Exp. Med. 2014; 7(8): 2343–2346.
  4. George J., George R., Dixit R.et al. Fat embolism syndrome. Lung India. 2013; 30(1): 47–53.
  5. Bin P., Huang R., Zhou X. Oxidation Resistance of the Sulfur Amino Acids: Methionine and Cysteine. Biomed Res Int. 2017; 2017: 9584932.
  6. Li Q., Cui J., Fang C., et al. S-Adenosylmethionine attenuates oxidative stress and neuroinflammation induced by amyloid-β through modulation of glutathione metabolism. Journal of Alzheimerʼs Disease. 2017; 58(2): 549–558.
  7. Singer M., De Santis V., Vitale D., Jeffcoate W. Multiorgan failure is an adaptive, endocrine-mediated, metabolic response to overwhelming. Lancet. 2004; 364(9433): 545–548.
  8. Novak Е.А., Mollen К.Р. Mitochondrial dysfunction in inflammatory bowel disease. Front. Ceel. Dev. Biol. 2015; 3: 62.
  9. Vincent J.L., Singer M. Critical care: advances and future perspectives. Lancet. 2010; 376(9749): 1354–1361.